Sun, Apr 20, 2014, 5:26 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

frobinso1 543 posts  |  Last Activity: Apr 18, 2014 11:44 AM Member since: May 4, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by kingfish543 Apr 17, 2014 10:09 PM
    frobinso1 frobinso1 Apr 18, 2014 11:44 AM Flag

    Does it anywhere indicate the Parkinson's UK (not MJFF) grant at the University of Leeds is a human study? I have assumed it's pre-clinical. Prana stated only once that first in human studies were targeted in 2014 year, and has reverted back to 2015 target for first in human studies of PBT434. I have seen nothing about the University of Leeds study going beyond pre-clinical/non-human work. I hope I am wrong. I reviewed the Parkinson's UK website and they seem to be an independent charity from MJFF.

  • I've been out of MVIS for quite awhile, but have kept it on the watchlist and occasionally check back in. I dipped my toes back in the water on Friday. If any of the old timers that can remember me are still in, I'll be trying to get up to speed on possible catalysts.

    I was curious if anything more is in the works for gaming. Sony is so into gaming I thought that maybe MVIS, via Sony might come through with a "game changer".

  • Reply to

    Tanzi Should Be Barred

    by jmlregoog Apr 4, 2014 1:21 PM
    frobinso1 frobinso1 Apr 4, 2014 2:26 PM Flag

    I think they should include mid-stage where we know there is decline in progress. If you think other big pharma's aren't looking at this trial and asking questions like, what if placebo improves in these early stage trials, what if our current psychological battery of tests (pick your standard test) are not precise enough to prove effect at the early stage? What if we actually completely halt cognitive decline but simply do not have good enough tests to detect a halt in decline?

    In an early stage MCI patient - don't we have a reduced chance of showing actual cognitive improvement - after all - we are not selling a pill that makes you smart beyond your pre-mci baseline - so should you expect to see actual improvement at an early stage mci trial?
    If you did show a slight improvement (likely the best you could hope for in the first place), will it be more pronounced than placebo effect that is a common occurrence in anyone taking a pill for something?

    You would have a much stronger chance at showing improvement in cognition in a mid-to-later stage trial - but early stage is always going to be more of a challenge. This trial proves that point.

    This trial is a harbinger of what might be faced by big pharma too across the board at early stage.

    And cocktail trials face a whole bunch of challenges when results are disappointing. Where do you go on the next step - from a statistical viewpoint you are increasing your possibilities for error to the point where you won't know what the next step to take is. Science may not guide you - is your next trial of xyz going to be to split up into xy, no z; xz no y, yx, no z, etc.? Will a cocktrail trial potentially run into a follow-on trial that is essentially four more combination trials, just to sort out the previous trial?

    I personally do not think science in AD has come far enough yet to entertain cocktail trials, but it's just my personal opinion. It is just thowing spaghetti at the wall to see what sticks.

  • Reply to

    fellow longs...

    by tdeank1 Mar 30, 2014 7:13 PM
    frobinso1 frobinso1 Mar 30, 2014 7:39 PM Flag

    Just ahead of boarding for dallas. Happy the news is coming. For Gout ah - another deadline met ;-)

  • Reply to

    Something I missed

    by kadaicher1 Mar 29, 2014 2:35 PM
    frobinso1 frobinso1 Mar 30, 2014 2:50 AM Flag

    Clearly, the fact that no deal has been reported with Reddy's supports that notion as well, with Dr. Peter Smith having brokered such a deal previous to his hire with Prana Biotech.

  • Reply to

    SSME Scale update

    by frobinso1 Mar 26, 2014 6:21 AM
    frobinso1 frobinso1 Mar 30, 2014 2:43 AM Flag

    There was a March 27th link to Alzheimer's prevention tips.

    Regarding "I think she's gonna blow!" On March 28th Rudy posted a picture from his hotel in Geneva at Int'l Alzheimer's meeting, where he is there with Colin Masters. If you look at the top center of the photo, It's of a an erupting fountain - might be descriptive of our post-results shareprice, and the eruption that will take place in the scientific community - metals theory going mainstream.

  • Reply to

    Trial extension question

    by onlineio Mar 30, 2014 12:18 AM
    frobinso1 frobinso1 Mar 30, 2014 2:35 AM Flag

    I believe that at least the first group in has been through cognitive testing, but scans using PIB/PET and the MRI; and also functional ability via ADCS-ADL-23 will not be performed till the end.

    Cognition testing via NTB & MMSE occur at 26 & 52 weeks, so some have been through that.

    Blood biomarkers evaluated at 13, 26, 39 & 52 weeks.

    All the safety exams occur at 4, 8, 13, 26, 39 & 52 weeks.

  • Reply to

    155000 shares...that's just silly

    by rt13101310 Mar 28, 2014 10:13 AM
    frobinso1 frobinso1 Mar 28, 2014 12:26 PM Flag

    Good move on your part, deerman. You will likely be highly rewarded soon.

  • Reply to


    by oliva1384 Mar 27, 2014 6:57 PM
    frobinso1 frobinso1 Mar 28, 2014 6:46 AM Flag

    It was commendable of you to offer up sage advice, Courtney. I'm on the long side and felt hedging with puts was too pricey. I'm biased long without a head for this result, come what may.

  • frobinso1 frobinso1 Mar 27, 2014 5:41 PM Flag

    U can still sell in after hours and move on - beats whining and eliminates risk

  • Reply to

    if clinical trial results are inconclusive

    by biotech_invest Mar 27, 2014 5:15 PM
    frobinso1 frobinso1 Mar 27, 2014 5:28 PM Flag

    You're full of it, Af circle jerk

  • Reply to

    SSME Scale update

    by frobinso1 Mar 26, 2014 6:21 AM
    frobinso1 frobinso1 Mar 27, 2014 7:17 AM Flag

    SSME Scale update - 1 more day and the needle is quivering near the top of the scale...I think she's gonna blow!

    Sentiment: Strong Buy

  • Reply to

    With a heavy heart

    by peteharmisan Mar 26, 2014 7:42 PM
    frobinso1 frobinso1 Mar 26, 2014 9:20 PM Flag

    I'm in the same boat Pete, but so far riding out results. First few days I felt like Linus without his security blanket, but it's tolerable and sometimes it's healthy to step back, whether in or out on your risk. Good luck on your trades.

    Sentiment: Strong Buy

  • Reply to

    Just a thought

    by gmanwicksy Mar 26, 2014 6:00 PM
    frobinso1 frobinso1 Mar 26, 2014 6:24 PM Flag

    That's why they took the stock down - to sell you puts at the price of a 90 year-old's insurance and to get you to sell your stock. Why play their game? If you had an ounce of conviction in the first place you would understand this means nothing.

    Sentiment: Strong Buy

  • The simple reason they are holding results until tomorrow is because on that very day in U.S.A. Viagra 27th March, 1998: The FDA approves the drug Viagra produced by Pfizer for use against impotence in men. It's amazing how nostalgic scientists and CEOs can be sometimes.

    At their partners request, of course. IT guy was the one testing out the new Pfizer Logo some months back.

    Sentiment: Strong Buy

  • Reply to

    Just a thought

    by gmanwicksy Mar 26, 2014 6:00 PM
    frobinso1 frobinso1 Mar 26, 2014 6:14 PM Flag

    based on that I think you should sell any stock if you own any. Why take a chance!? he he

    Sentiment: Strong Buy

  • Reply to

    What is a drug that can impact AD worth?

    by dogslifebowwow Mar 26, 2014 6:39 AM
    frobinso1 frobinso1 Mar 26, 2014 6:57 AM Flag

    It is staggering what a disease-modifying drug would be worth. Compelling results that validate the metals theory would rock the world. The convenience of PBT2, being a pill that crosses the blood-brain barrier with a compelling safety profile is astounding, and may find it's way quickly to market.

    Sentiment: Strong Buy

  • Reply to

    SSME Scale update

    by frobinso1 Mar 26, 2014 6:21 AM
    frobinso1 frobinso1 Mar 26, 2014 6:47 AM Flag

    In the back of my mind I keep thinking about the Key Executive appointment of Dr. Peter Smith specifically focused on business development. Another example of social media silence as one wonder's what acitivities are going on along the lines of business development. This is an individual who has previously negotiated a commercial agreement with our current manufacturer of PBT2 - Dr. Reddy's of India - yet no deal. Seems to say Partnership.

    I wonder if non-disclosure agreements made some years back are still in effect? Geoffrey's most recent interview talked about being open to partnering, and that they were going to be "reaction ready".

    With the Elsevier conference, the Biotech Showcase 2014, and now another partnering presentation on the 28th it could be a very nice time to have a position in Prana Biotech.

    We have the recent Credit Suisse connection. Fidelity on board, now PBT is in the ASX 300, still way under-owned institutionally in the U.S.

    Sentiment: Strong Buy

  • frobinso1 by frobinso1 Mar 26, 2014 6:21 AM Flag

    Needle is registering strongly on the scale. Complete Social Media silence since 3/18. Eight days and counting. Eliminating the SuperBrain posts there has not been a post since his 3/12 interview with the AWARE show - fourteen days.

    Confererence Presentation in two days. Green close on ASX with buying interest shown at the first part of the session, pulling back, then closing strongly at the high of the day.

    Sentiment: Strong Buy

  • Reply to

    Expecting results Thursday

    by brewman228 Mar 25, 2014 9:23 PM
    frobinso1 frobinso1 Mar 25, 2014 9:30 PM Flag

    Correction. From the Pfizer offices ;-) "We'll be reaction ready"

1.89+0.15(+8.62%)Apr 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.